Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes
April 1, 2023
New criteria for response to therapy in high grade MDS, focuses on pt centered outcomes.
Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors
April 1, 2023
Neoadjuvant immunotherapy is gaining momentum in breast (triple negative) and lung cancer, now showing promise in MSI high tumors.
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
April 1, 2023
Confirms what we already know. No real surprises.
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer
April 1, 2023
In this study, Cetuximab beat Bevacizumab in left sided KRAS wild type colon cancer.
Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study
April 1, 2023
Three trial updates confirm what we already know and practice.
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
April 1, 2023
Confirms what we already know. No real surprises.
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
April 1, 2023
Confirms what we already know. No real surprises.
Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial
April 1, 2023
Somewhat disappointing as this was a negative study, however it is still an option for patients who are not candidates for mFOLFIRINOX.
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651
April 1, 2023
Although immunotherapy did not beat chemotherapy but was non inferior and with more favorable safety.
Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial
April 1, 2023
I welcome additional comments from our Radiology Oncologists, but it seems patients may not need axillary surgery, this eliminated adverse events such as lymphedema.